Drug Database · Clinicians

Benzoyl peroxide

Brands (4) Benzac Spots Treatment, Benzoper, Acne Drying Gel…Show all

US brand (reference label): Epsolay; not a Philippine-registered brand.

Keratolytic; Anti-acne PH FDA category

Rx · Prescription drugOTC · Over-the-counter7 PH productsPNF-listed
Dispensing: Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 641981e6-460b-44dd-8146-306c47e5367c, version date August 11, 2025 (Epsolay · Mayne Pharma Commercial LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults. EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults. (1)

Contraindications

4 CONTRAINDICATIONS EPSOLAY is contraindicated in patients with a history of hypersensitivity reactions to benzoyl peroxide or any components of the formulation in EPSOLAY [see Warnings and Precautions (5.1)]. A history of a serious hypersensitivity reactions to benzoyl peroxide or any component of the formulation in EPSOLAY. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

2 DOSAGE AND ADMINISTRATION Before initial use, prime the pump until the first drop of cream is released. Apply a pea-sized amount of EPSOLAY once daily in a thin layer to each area of the face (forehead, chin, nose, each cheek) on clean and dry skin. Avoid the eyes, lips and mouth. Wash hands after application. EPSOLAY may bleach hair or colored fabric.

EPSOLAY is for topical use only. Not for oral, ophthalmic, or intravaginal use. Discard unused EPSOLAY 60 days after first use. Apply to the affected areas once daily. (2) Wash hands after application. (2) Not for oral, ophthalmic, or intravaginal use. (2)

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of EPSOLAY for the treatment of inflammatory lesions of rosacea have not been established in pediatric patients.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 733 subjects in the clinical trials of EPSOLAY, 127 (17%) subjects were 65 and over, while 37 (3%) subjects were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.

Dosage forms

Philippines

  • Topical gel: 50 mg/g
  • Gel: 50 mg/g
  • W/w) gel: 50 mg/g (5 %

Registered products in the Philippines

7 products registered with the Food and Drug Administration (FDA) Philippines list Benzoyl peroxide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products7
Philippine FDA-registered products for Benzoyl peroxide
Package insert
Acne Drying GelBenzoyl Peroxide
50 mg/g (5%w/w) GelAluminum Tube x 5 g and 20 g (Box of 1's)
Rx
Zee LaboratoriesIndia
Intelligent Beauty Skin Solutions, Inc.Importer: Eon Pharmatek, Inc.
DR-XY47316
Jun 29, 2031
Benzac Spots TreatmentBenzoyl Peroxide
10% GelLDPE Plastic Tube x 60 g (Box of 1 's)
OTC
Laboratoires GaldermaFrance
Importer: Galderma Philippines, Inc.
DR-XY1735
Dec 9, 2031
Benzac Spots TreatmentBenzoyl Peroxide
10% Gel
OTC
Laboratoires Galderma
Importer: GALDERMA PHILIPPINES, INC.
DR-XY17355
Dec 9, 2026
Benzac Spots TreatmentBenzoyl Peroxide
50 mg/g (5% w/w) Gel
OTC
Laboratoires Galderma
Importer: Galderma Philippines, Inc.
DR-XY16211
Dec 9, 2026
BenzomedBenzoyl Peroxide
50mg/g (5% w/w) Topical GelAluminum Collapsible Tube x 15g (Box of l's)
OTC
Blossom PharmaceuticalsIndia
Medinova Pharmaceutical Inc.
DRP-11205
Feb 11, 2027
BenzoperBenzoyl Peroxide
50 mg/g (5% w/w) Topical GelAluminum Collapsible Tube x 5 g (Box of 1's); Aluminum Collapsible Tube x 20 g (Box of 1's)
Rx
Zee LaboratoriesIndia
Eon Pharmatek, Inc.Importer: Eon Pharmatek, Inc
DR-XY42508
Sep 2, 2028
BenzoperBenzoyl Peroxide
50 mg/g (5% w/w) Topical GelAluminum Collapsible Tube x 5 g (Box of 1's); Aluminum Collapsible Tube x 20 g (Box of 1's)
Rx
Zee LaboratoriesIndia
Eon Pharmatek Inc.
DRP-15047
Sep 2, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Cream, 5%. Each gram of EPSOLAY contains 50 mg of benzoyl peroxide in a white to off-white base. Cream, 5%. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with the use of benzoyl peroxide products. (5.1)
  • Skin irritation/contact dermatitis: Erythema, scaling, dryness, stinging/burning, irritation and allergic contact dermatitis may occur with use of EPSOLAY and may necessitate discontinuation. (5.2)
  • Photosensitivity: Avoid or minimize exposure to natural or artificial sunlight and use sun protection measures. (5.3)
5.1 Hypersensitivity

5.1 Hypersensitivity Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, have been reported with the use of benzoyl peroxide products. If a serious hypersensitivity reaction occurs, discontinue EPSOLAY immediately and initiate appropriate therapy.

5.2 Skin Irritation/Contact Dermatitis

5.2 Skin Irritation/Contact Dermatitis Erythema, scaling, dryness and stinging/burning may be experienced with use of EPSOLAY. Irritation and contact dermatitis may occur. Apply a moisturizer and discontinue EPSOLAY if symptoms do not improve. Avoid application of EPSOLAY to cuts, abrasions, eczematous or sunburned skin.

5.3 Photosensitivity

5.3 Photosensitivity Benzoyl peroxide may increase sensitivity to sunlight. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using EPSOLAY. Instruct the patient to implement sun protection measures (e.g., sunscreen and loose- fitting clothes) when sun exposure cannot be avoided.

Discontinue EPSOLAY at the first evidence of sunburn.

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS Most common adverse reactions (incidence ≥ 1%) are application site reactions: pain, erythema, pruritis and edema. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two randomized, double-blind, vehicle-controlled trials, adult subjects with rosacea applied EPSOLAY (N = 488) or vehicle (N = 234) once daily for 12 weeks. The majority of subjects were Caucasian (93%) and female (73%) with a mean age of 51 years. Table 1 presents the most common adverse reactions occurring in ≥ 1% of subjects treated with EPSOLAY and more frequently than in subjects treated with vehicle.

Table 1: Adverse Reactions Occurring in ≥ 1% of Subjects Treated with EPSOLAY and with Greater Frequency than Subjects Treated with Vehicle EPSOLAY N=488 Vehicle N=234 Application site pain 11 (2%) 2 (1%) Application site erythema 11 (2%) 2 (1%) Application site pruritus 6 (1%) 1 (<1%) Application site edema Application site edema includes: application site swelling and application site edema 4 (1%) 0 (0%) During the clinical trials, local tolerability evaluations were conducted at baseline and at each study visit by assessment of dryness, itching, scaling and stinging/burning. Table 2 presents the local tolerability assessments by severity grade at Week 12.

Table 2: Facial Cutaneous Tolerability Assessment Sign/Symptom EPSOLAY N=455 Of the 488 subjects treated with EPSOLAY, 455 subjects had local tolerability assessments at Week 12. Severity at Week 12 Mild Moderate Severe Dryness 25% 7% 0% Itching 24% 6% 0% Scaling 13% 4% 0% Stinging/Burning 20% 3% 1% In a 40-week open-label extension safety study (for a total of up to 52 weeks of treatment) the frequency and severity of local tolerability signs and symptoms at Week 52 were comparable to those reported at Week 12.

Adverse reaction frequency tables (US label) US FDA label
Table 1: Adverse Reactions Occurring in ≥ 1% of Subjects Treated with EPSOLAY and with Greater Frequency than Subjects Treated with Vehicle
EPSOLAY N=488Vehicle N=234
Application site pain11 (2%)2 (1%)
Application site erythema11 (2%)2 (1%)
Application site pruritus6 (1%)1 (<1%)
Application site edemaApplication site edema includes: application site swelling and application site edema4 (1%)0 (0%)
Table 2: Facial Cutaneous Tolerability Assessment
Sign/SymptomEPSOLAY N=455Of the 488 subjects treated with EPSOLAY, 455 subjects had local tolerability assessments at Week 12.
Severity at Week 12
MildModerateSevere
Dryness25%7%0%
Itching24%6%0%
Scaling13%4%0%
Stinging/Burning20%3%1%

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary The systemic exposure of benzoyl peroxide is unknown. Based on the published literature, benzoyl peroxide is metabolized to benzoic acid (an endogenous substance), which is eliminated in the urine. Hence, maternal use is not expected to result in fetal exposure to the drug. Animal reproductive studies have not been conducted with EPSOLAY or benzoyl peroxide.

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Mechanism of action

12.1 Mechanism of Action Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action in the treatment of rosacea is unknown.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics The pharmacodynamics of EPSOLAY in the treatment of rosacea are unknown.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

12.3 Pharmacokinetics Benzoyl peroxide is absorbed by the skin where it is converted to benzoic acid, an endogenous substance, which is eliminated in the urine.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Benzoyl peroxide is absorbed by the skin where it is converted to benzoic acid, an endogenous substance, which is eliminated in the urine. The systemic exposure of benzoyl peroxide following the application of EPSOLAY was not assessed.

Formulary and pricing (Philippines)

Formulary and coverage

Philippine National FormularyListed as Benzoyl Peroxide
PNF listingGel: 5%, 20 g tube
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Epsolay · Mayne Pharma Commercial LLC [US FDA-approved label, version 2, August 11, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=641981e6-460b-44dd-8146-306c47e5367c
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .